Vilobelimab Antibody
Vilobelimab (CaCP-29) is a chimeric monoclonal antibody that specifically inhibits the complement protein C5a, thereby blocking neutrophil activation. It is a valuable research tool for investigating mechanisms of systemic inflammation, including in models of severe COVID-19 and other complement-mediated pathologies, in both in vitro and in vivo experimental settings.
Product Specifications
Product Name Alternative
IFX1, IFX-1, CaCP29, CaCP-29, ComplementSystem, complement 5a receptor (C5aR), Complement System, SARSCoV, SARS-CoV
Target
Complement System, SARS-CoV
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation, Infectious Disease & Virology
Concentration
6 mg/mL
Purity
95.00% (May vary between batches)
Molecular Weight
145.86 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human GRB2 (Growth Factor Receptor-Bound Protein 2) Recombinant Protein 6xHis-GST Tagged